Get live statistics and analysis of truth.phd's profile on X / Twitter

I have my entire net worth in $LULU, and I'm not planning to sell it anytime soon. Lululemon remains a compelling long-term hold despite a steep 2025 selloff, thanks to its powerful brand, zero debt, and resilient profitability even in softer US retail conditions. Its aggressive international expansion, especially in China and new markets, positions the company for robust future growth, while ongoing product innovation and the company’s loyal customer base strengthen its competitive edge. Trading at a historically attractive valuation, $LULU offers significant rebound potential for investors seeking durable growth and reliable financial quality in the next cycle.

Rockwell Medical ($RMTI): Powering the $143B Kidney Dialysis Market's Bright Future This comprehensive analysis examines the kidney dialysis market with a focus on how aging populations will affect future demand, the competitive landscape of manufacturers in the US, Rockwell

$RMTI Buy the fear, sell the future news. Accumulating...

Why $RMTI is a BUY? Manufacturing Complexity: Rockwell Medical's manufacturing processes range from moderate complexity for standard hemodialysis concentrates to higher complexity for pharmaceutical products like Triferic. The acquisition of Evoqua's fully automated operations has significantly enhanced their manufacturing capabilities. Patent Protection: While they have limited patent protection for their core hemodialysis concentrates business, they maintain stronger protection for Triferic, providing competitive advantage in the iron delivery space. Market Position: Rockwell holds approximately 25% of the U.S. dialysis concentrates market in a duopoly structure with Fresenius (75%), with significant barriers to entry protecting this position. Competitive Edge: Their advantage stems from vertically integrated manufacturing and distribution, strategic facility locations, automation technology, quality systems (ISO 13485, cGMP), and proprietary formulations. Global Reach: They've established an extensive distribution network spanning over 30 countries with strategic partnerships enhancing their global capabilities.

$RMTI The global intravenous (IV) iron drugs market is on a strong growth trajectory, driven by the increasing prevalence of iron deficiency anemia, particularly among patients with chronic conditions. Projected to rise from USD 3.27 billion in 2024 to USD 6.63 billion by 2032 with a compound annual growth rate of 9.31%, the market offers significant opportunities for companies like Rockwell Medical. As a key player in hemodialysis products and anemia management, Rockwell is expanding its presence through strategic partnerships and distribution agreements, with recent financial performance showing net sales surpassing $100 million in 2024, including a record $22.7 million in the first quarter. Estimating Rockwell Medical's revenue potential in the IV iron drugs market, a conservative projection suggests IV iron therapies could contribute $10-20 million annually in the near term, potentially growing to $20-40 million by 2032 as the market expands, assuming sustained growth and successful strategy execution. However, this estimation is speculative due to the lack of specific IV iron revenue breakdowns, and factors like competition and regulatory challenges could impact actual figures. Rockwell remains well-positioned to capitalize on market growth, supported by new distribution agreements expected to add $1 million annually and a strong financial foundation.

$RMTI Earnings Call: Final Boarding Call! 🚂 Monday morning's earnings call is just 2 market days away! Two days remain to evaluate Rockwell Medical before potential market movement following their financial revelations. Consider your position now-the train leaves the station Monday morning! ⏱️ Remember to research thoroughly before any investment decision.

I have my entire net worth in $LULU, and I'm not planning to sell it anytime soon. Lululemon remains a compelling long-term hold despite a steep 2025 selloff, thanks to its powerful brand, zero debt, and resilient profitability even in softer US retail conditions. Its aggressive international expansion, especially in China and new markets, positions the company for robust future growth, while ongoing product innovation and the company’s loyal customer base strengthen its competitive edge. Trading at a historically attractive valuation, $LULU offers significant rebound potential for investors seeking durable growth and reliable financial quality in the next cycle.

$RMTI Buy the fear, sell the future news. Accumulating...

Rockwell Medical ($RMTI): Powering the $143B Kidney Dialysis Market's Bright Future This comprehensive analysis examines the kidney dialysis market with a focus on how aging populations will affect future demand, the competitive landscape of manufacturers in the US, Rockwell

Why $RMTI is a BUY? Manufacturing Complexity: Rockwell Medical's manufacturing processes range from moderate complexity for standard hemodialysis concentrates to higher complexity for pharmaceutical products like Triferic. The acquisition of Evoqua's fully automated operations has significantly enhanced their manufacturing capabilities. Patent Protection: While they have limited patent protection for their core hemodialysis concentrates business, they maintain stronger protection for Triferic, providing competitive advantage in the iron delivery space. Market Position: Rockwell holds approximately 25% of the U.S. dialysis concentrates market in a duopoly structure with Fresenius (75%), with significant barriers to entry protecting this position. Competitive Edge: Their advantage stems from vertically integrated manufacturing and distribution, strategic facility locations, automation technology, quality systems (ISO 13485, cGMP), and proprietary formulations. Global Reach: They've established an extensive distribution network spanning over 30 countries with strategic partnerships enhancing their global capabilities.

$RMTI The global intravenous (IV) iron drugs market is on a strong growth trajectory, driven by the increasing prevalence of iron deficiency anemia, particularly among patients with chronic conditions. Projected to rise from USD 3.27 billion in 2024 to USD 6.63 billion by 2032 with a compound annual growth rate of 9.31%, the market offers significant opportunities for companies like Rockwell Medical. As a key player in hemodialysis products and anemia management, Rockwell is expanding its presence through strategic partnerships and distribution agreements, with recent financial performance showing net sales surpassing $100 million in 2024, including a record $22.7 million in the first quarter. Estimating Rockwell Medical's revenue potential in the IV iron drugs market, a conservative projection suggests IV iron therapies could contribute $10-20 million annually in the near term, potentially growing to $20-40 million by 2032 as the market expands, assuming sustained growth and successful strategy execution. However, this estimation is speculative due to the lack of specific IV iron revenue breakdowns, and factors like competition and regulatory challenges could impact actual figures. Rockwell remains well-positioned to capitalize on market growth, supported by new distribution agreements expected to add $1 million annually and a strong financial foundation.

$RMTI Earnings Call: Final Boarding Call! 🚂 Monday morning's earnings call is just 2 market days away! Two days remain to evaluate Rockwell Medical before potential market movement following their financial revelations. Consider your position now-the train leaves the station Monday morning! ⏱️ Remember to research thoroughly before any investment decision.